The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Opdivo (nivolumab) on April 11, 2025. This approval, designated as BLA 125554 S-129, was based on new efficacy data submitted by Bristol Myers Squibb.
Background
Nivolumab, marketed as Opdivo, is an immunotherapy drug that functions as a programmed death-1 (PD-1) blocking antibody. It is developed by Bristol Myers Squibb. Opdivo has received multiple prior approvals for various cancer indications, establishing its role in immuno-oncology. This supplemental application specifically addresses new efficacy data related to its therapeutic profile, indicating an expansion or refinement of its approved uses based on additional clinical evidence.
What this means
This supplemental approval for Opdivo (nivolumab) signifies that the FDA has reviewed and accepted additional data supporting the drug's efficacy. While the specific details of the new indication, patient population, or updated treatment regimen are not provided in this update, such approvals typically lead to an update in the drug's prescribing information. This could translate to an expanded therapeutic option for patients, potentially in a new cancer type, an earlier line of therapy, or a specific subset of patients who may benefit from nivolumab. For clinicians, researchers, and patient advocates, this approval reinforces the therapeutic value of nivolumab and potentially broadens its applicability in cancer treatment strategies, offering new avenues for patient care and further research into its optimal use.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for Opdivo (nivolumab), identified as BLA 125554 S-129, was granted on April 11, 2025, and is publicly accessible on accessdata.fda.gov.